Schaeffer's 43rd Anniversary Stock Picks in 2024

Option Bulls Rush Gilead Sciences, Inc. (GILD) Amid Broader Biotech Bounce

Gilead Sciences, Inc. (NASDAQ:GILD) is getting a much-needed lift from sector tailwinds

Sep 20, 2016 at 2:00 PM
facebook X logo linkedin


Biotech stocks are outperforming today, on the heels of some major M&A headlines within the sector. Among the drugmakers heading higher on sector tailwinds is Gilead Sciences, Inc. (NASDAQ:GILD) -- which is up 3.2% at $81.54, and in the crosshairs of options traders.

Diving right in, GILD call options are changing hands at two times the usual intraday rate. The most active strike is the October 82.50 call, where traders may be buying new out-of-the-money positions, hoping the underlying stock will topple $82.50 by the close on Friday, Oct. 21 -- when the newly front-month options expire. Meanwhile, even shorter-term bulls are buying to open the weekly 9/23 82-strike call, targeting additional end-of-week upside for GILD.

Today's call buying merely echoes the prevailing trend in the stock's options pits. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have bought to open triple the number of calls as puts in the past two weeks. The resultant call/put volume ratio of 3.13 ranks only 12 percentage points from a 12-month peak.

Further underscoring GILD's call-skew is its Schaeffer's put/call open interest ratio (SOIR) of 0.45, with calls more than doubling puts among options expiring in the next three months. Of note, this SOIR rests only 5 percentage points from an annual low.

Now appears to be a great time to purchase premium on short-term Gilead options. The stock's Schaeffer's Volatility Index (SVI) of 21% outstrips only 4% of readings from the prior year. Additionally, GILD's 30-day at-the-money implied volatility of 21.8% rests in the bottom 8% of all readings from the last 12 months.

Obviously, today's sharp upside move is stoking good vibes in the options pits. However, from a longer-term perspective, Gilead Sciences, Inc. (NASDAQ:GILD) has been nothing short of a technical trainwreck. Year-over-year, the shares have shed almost 23% of their value, and continue to face pressure at their descending 20-week moving average -- located just overhead, at $82.26.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Nvidia and its powerful chips are the face of artificial intelligence.

But while everyone’s patting Nvidia on the back for record earnings…

It’s quietly moved on to the next phase of AI it plans to conquer…

Nvidia recently unveiled essential blueprints for this crucial $1 trillion pivot.

Click here now and find out about the three companies Nvidia absolutely needs to succeed in this vital new AI frontier. (ad)
schaeffer's opening view daily market newsletter

                                                                                                   
๐Ÿš€ Try Options Under $5 Trade Alerts 
Target +150% Profit w/RT Entry&Exit

                                                                                                    

 
 

                                                                                                   
This stock is paying its highest dividend
in 15 years . . . ๐Ÿ“ˆ (c/o Investors Alley)

                                                                                                    

 


                                                                                                   
Top 10 Investment Picks Poised For
Major Upside Before 2025 ๐Ÿ’ฐ
 (FREE)

                                                                                                    

 

join schaeffer's market recap daily stock marketnewsletter

 

                                               ad                                                  
Some of Nvidia’s partners have already
surged as much as 4,744%. This is next …

                                                ad